Results 181 to 190 of about 29,485 (291)

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies. [PDF]

Front Immunol
Püsküllüoğlu M, Pacholczak-Madej R.
europepmc   +1 more source

Cutaneous Toxicities Associated With Amivantamab in Patients With Non‐Small Cell Lung Cancer: A Systematic Review

International Journal of Dermatology, EarlyView.
Ioannis‐Alexios Koumprentziotis, Aikaterini Bakella, Antonis Tsimpidakis, Alexander Stratigos, Vasiliki Nikolaou   +4 more
wiley   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

European Journal of Haematology, Volume 117, Issue 2, Page 320-337, August 2026.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +14 more
wiley   +1 more source

Advances in the clinical application of bispecific antibodies in cancer therapy. [PDF]

iScience
Zhou S, Li F, Niu M, Wu K, Li T, Yi M.
europepmc   +1 more source

Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah, Werner Dammermann, Stefan Lueth   +2 more
wiley   +1 more source

Efficacy and safety of approved cellular therapies and bispecific antibodies in solid tumors: the current state. [PDF]

Discov Oncol
Jafry RZ, Qamar SB, Irfan S, Abid MA, Mohlere V, Maithel N, Jafri SH, Awasthi S, Srour S, Vaziri IA, Abid MB.   +10 more
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, Volume 159, Issue 2, Page 460-466, 15 July 2026.
What's new? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis. [PDF]

Ann Hematol
Spataro F, Desantis V, Einsele H, Dammacco F, Vacca A, Ria R, Solimando AG.   +6 more
europepmc   +1 more source

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source

Blinatumomab Utilization in Pediatric B‐Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Background Blinatumomab is a bispecific T‐cell engager approved for the treatment of pediatric B‐cell acute lymphoblastic leukemia (B‐ALL). Outpatient home infusion reduces hospitalization burden and optimizes resource utilization, but is logistically challenging.
Angela Parra del Riego, Kellee Parker, William C. Thomsen, James B. Ford, Mallorie B. Heneghan, David Spencer Mangum, Jennifer L. McNeer, Luke D. Maese, Claire E. F. Miller, Richard Lemons, Taumoha Ghosh   +10 more
wiley   +1 more source